SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma

Summary: Drug resistance prominently hampers the effects of systemic therapy of sorafenib to hepatocellular carcinoma (HCC). Epigenetics have critical regulatory roles in drug resistance. However, the contributions of histone methylatransferase SET and MYND domain containing 3 (SMYD3) to sorafenib r...

Full description

Bibliographic Details
Main Authors:	Shanshan Wang, Xin You, Xiaoshu Liu, Fengwei Zhang, Hongjuan Zhou, Xuechai Shang, Long Cai
Format:	Article
Language:	English
Published:	Elsevier 2023-07-01
Series:	iScience
Subjects:	Drugs Epigenetics Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589004223010714

Similar Items

Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma
by: Shanshan Wang, et al.
Published: (2020-03-01)

Targeting Smyd3 by next-generation antisense oligonucleotides suppresses liver tumor growth
by: Haroula Kontaki, et al.
Published: (2021-05-01)

New open conformation of SMYD3 implicates conformational selection and allostery
by: Nicholas Spellmon, et al.
Published: (2016-12-01)

SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways
by: Cinzia Bottino, et al.
Published: (2020-01-01)

Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition
by: Grégory Fouquet, et al.
Published: (2022-02-01)

The Effect of Alpha Mangostin on Epithelial-Mesenchymal Transition on Human Hepatocellular Carcinoma HepG2 Cells Surviving Sorafenib via TGF-β/Smad Pathways
by: Syarinta Adenina, et al.
Published: (2020-08-01)

SMYD2 promoter DNA methylation is associated with abdominal aortic aneurysm (AAA) and SMYD2 expression in vascular smooth muscle cells
by: Bradley J. Toghill, et al.
Published: (2018-03-01)

DYRK1A reinforces epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma via cooperatively activating STAT3 and SMAD
by: Yang-ling Li, et al.
Published: (2022-06-01)

The Role of Histone Variants in the Epithelial-To-Mesenchymal Transition
by: Imtiaz Nisar Lone, et al.
Published: (2020-11-01)

Overexpression of SMYD3 Promotes Autosomal Dominant Polycystic Kidney Disease by Mediating Cell Proliferation and Genome Instability
by: Ewud Agborbesong, et al.
Published: (2024-03-01)

Epigenetic regulation of SMAD3 by histone methyltransferase SMYD2 promotes lung cancer metastasis
by: Kwangho Kim, et al.
Published: (2023-05-01)

Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells
by: Li-Zhu Liao, et al.
Published: (2020-12-01)

Repression of Smad3 by silencing Robo1 attenuates epithelial-mesenchymal transition in tracheobronchial stenosis
by: Chunyan He, et al.
Published: (2023-09-01)

Characterizing the Role of SMYD2 in Mammalian Embryogenesis—Future Directions
by: Dillon K. Jarrell, et al.
Published: (2020-05-01)

Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer
by: Bo Dong, et al.
Published: (2020-11-01)

TGF-β1 induced deficiency of linc00261 promotes epithelial–mesenchymal-transition and stemness of hepatocellular carcinoma via modulating SMAD3
by: Zhanjun Chen, et al.
Published: (2022-02-01)

XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma
by: Zengbin Wang, et al.
Published: (2023-04-01)

Epigenetic reprogramming of epithelial-mesenchymal transition promotes ferroptosis of head and neck cancer
by: Jaewang Lee, et al.
Published: (2020-10-01)

Sinomenine Relieves Airway Remodeling By Inhibiting Epithelial-Mesenchymal Transition Through Downregulating TGF-β1 and Smad3 Expression In Vitro and In Vivo
by: Hongjuan He, et al.
Published: (2021-11-01)

The SMYD family proteins in immunology: An update of their obvious and non-obvious relations with the immune system
by: Teresa Rubio-Tomás
Published: (2021-06-01)

Lyn regulates epithelial–mesenchymal transition in CS-exposed model through Smad2/3 signaling
by: Xiaobo Liang, et al.
Published: (2019-09-01)

Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
by: Jiejie Dong, et al.
Published: (2017-01-01)

14-3-3ε overexpression contributes to epithelial-mesenchymal transition of hepatocellular carcinoma.
by: Tzu-An Liu, et al.
Published: (2013-01-01)

KIAA1429 mediates epithelial mesenchymal transition in sorafenib‐resistant hepatocellular carcinoma through m6A methylation modification
by: Ye Kuang, et al.
Published: (2023-03-01)

Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer
by: Joëlle Roche, et al.
Published: (2017-06-01)

Genomics and Prognosis Analysis of Epithelial-Mesenchymal Transition in Glioma
by: Chuming Tao, et al.
Published: (2020-02-01)

ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma
by: Zhenyu Zhou, et al.
Published: (2019-01-01)

Targeting Epigenetic Changes Mediated by Members of the SMYD Family of Lysine Methyltransferases
by: Alyssa Padilla, et al.
Published: (2023-02-01)

Sorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cells.
by: Juyong Zhang, et al.
Published: (2013-01-01)

Role of IQGAP3 in metastasis and epithelial–mesenchymal transition in human hepatocellular carcinoma
by: Yongjie Shi, et al.
Published: (2017-08-01)

Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription
by: Zongcheng Yang, et al.
Published: (2023-05-01)

Histone Methyltransferase SETD1A Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis Through Epigenetic Reprogramming of Snail in Gastric Cancer
by: Jugang Wu, et al.
Published: (2021-06-01)

Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
by: Ilaria Romito, et al.
Published: (2021-11-01)

SMAD2/3-SMYD2 and developmental transcription factors cooperate with cell cycle inhibitors to guide tissue formation
by: Militi, S, et al.
Published: (2024)

MicroRNA-10b regulates epithelial–mesenchymal transition by modulating KLF4/KLF11/Smads in hepatocellular carcinoma
by: Gulibaha Hujie, et al.
Published: (2018-01-01)

SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters
by: Heyun Zhang, et al.
Published: (2021-07-01)

Goosecoid promotes the metastasis of hepatocellular carcinoma by modulating the epithelial-mesenchymal transition.
by: Tong-Chun Xue, et al.
Published: (2014-01-01)

CircFGGY Inhibits Cell Growth, Invasion and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma via Regulating the miR-545-3p/Smad7 Axis
by: Kun-Liang Feng, et al.
Published: (2022-05-01)

CRTC2 activates the epithelial–mesenchymal transition of diabetic kidney disease through the CREB-Smad2/3 pathway
by: Yujie Li, et al.
Published: (2023-10-01)

MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
by: Akihiro Hirao, et al.
Published: (2021-09-01)